

May 5, 2018

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated May 5, 2018 titled "Zydus receives final approval for Succinylcholine Chloride Injection USP and tentative approval for Plerixafor Injection from the USFDA".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval for Succinylcholine Chloride Injection USP and tentative approval for Plerixafor Injection from the USFDA

Ahmedabad, 5 May, 2018

Zydus Cadila has received the final approval from the USFDA to market Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) multiple-dose vials. It is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group also received the tentative approval for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), single-dose vial. It is used to mobilize hematopoietic stem cells into the bloodstream for their collection & subsequent transplantation in patients with certain type of blood cancers. It will be manufactured at Alidac Pharmaceuticals Ltd., a wholly owned subsidiary of Cadila Healthcare Ltd., located at the pharma SEZ in Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
